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Abstract
Amyotrophic Lateral Sclerosis is a fatal, progressive neurodegenerative disease character-
ized by loss of motor neuron function for which there is no effective treatment. One of the
main difficulties in developing new therapies lies on the multiple events that contribute to
motor neuron death in amyotrophic lateral sclerosis. Several pathological mechanisms
have been identified as underlying events of the disease process, including excitotoxicity,
mitochondrial dysfunction, oxidative stress, altered axonal transport, proteasome dysfunc-
tion, synaptic deficits, glial cell contribution, and disrupted clearance of misfolded proteins.
Our approach in this study was based on a holistic vision of these mechanisms and the use
of computational tools to identify polypharmacology for targeting multiple etiopathogenic
pathways. By using a repositioning analysis based on systems biology approach (TPMS
technology), we identified and validated the neuroprotective potential of two new drug com-
binations: Aliretinoin and Pranlukast, and Aliretinoin and Mefloquine. In addition, we esti-
mated their molecular mechanisms of action in silico and validated some of these results in
a well-established in vitromodel of amyotrophic lateral sclerosis based on cultured spinal
cord slices. The results verified that Aliretinoin and Pranlukast, and Aliretinoin and Meflo-
quine promote neuroprotection of motor neurons and reduce microgliosis.
Introduction
Since Charcot first description, Amyotrophic Lateral Sclerosis (ALS) is considered an adult-
onset disease characterized by severe degeneration of lower (spinal or bulbar) and upper (corti-
cal) motoneurons (MNs). Approximately two thirds of ALS patients have a spinal form of the
disease (limb onset) and present symptoms related to focal weakness and wasting which may
start either distally or proximally in the upper and lower limbs. Paralysis is progressive and
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leads to death due to respiratory failure within 2–3 years for bulbar onset cases and within 3–5
years for limb onset [1]. Despite all the recent insights into the molecular mechanism of the
disease, no improvement in the therapeutic options for ALS patients has been obtained during
the past two decades. A large number of preclinical studies have been performed in rodent
models of ALS to prevent, reverse or modulate the disease process. So far, none of these thera-
peutic strategies has been successfully replicated in clinical trials. As a consequence, besides
riluzole, 2-amino-6-trifluoromethoxybenzothiazole [2], only palliative treatments are applied
to improve the quality of life of ALS patients. Riluzole increases the life span of the patients by
an average of 2–3 months [3], an effect that was reproduced in different clinical trials [4]. The
mechanism of action (MoA) is linked to the blockade of sodium channels, inactivation of volt-
age-dependent calcium channels, and blockade of sodium-dependent glutamate release. The
protective effect of riluzole has been examined in various models where excitotoxicity has an
important role in MN death including organotypic-based models [5] and animal models of spi-
nal cord injury [6].
In most cases (~90%), termed sporadic ALS (sALS), the etiology is unknown, although
some inherited mutations found in familial cases (fALS) have allowed significant advances in
the study of the etiopathogenesis during the last decades [7].
The discovery of new genes implicated in ALS and the existence of common mechanisms
found in most of the genes have pointed to new insights into the pathogenic pathways. Bioin-
formatics analysis of their annotated functions reveal an enrichment in processes such as endo-
cytosis and impaired vesicle (Alsin, vesicle-associated membrane protein-associated protein B/
C (VAPB), optineurin (OPTN), transitional endoplasmic reticulum ATPase (VCP)), axonal
transport and organelle trafficking (spatacsin), compromised autophagy (charged multivesicu-
lar body protein 2b (CHMP2B)) and protein degradation, in the unfolded protein response
(ubiquilin-2 (UBQLN2), sigma non-opioid intracellular receptor 1 (SIGMAR1)), transcription
regulation and RNA metabolism (C9orf72, TAR DNA-binding protein 43 (TARDBP), probable
helicase senataxin (SETX)), as well as in mitochondria-dependent oxidative stress [8]. How-
ever, ALS is a heterogeneous disease, not only genetically, but also clinically, due to variability
in several factors such as age, gender, site of onset and rate of progression. Hence, instead of
targeting specific disease-causing genes an alternative is to target pathogenic mechanisms.
Thus, the existence of several evidences for a complex interplay between glutamate excitotoxi-
city, mitochondrial dysfunction, glial activation, defective protein misfolding, oxidative dam-
age and defective RNA processing highlights the value of molecular interaction profiles in the
discovery of novel multicomponent therapies [9,10].
Systems biology has recently emerged as a new discipline that addresses this need by consid-
ering living organisms as networks of interacting genes, proteins and biochemical reactions.
Given the complexity inherent to human physiology, systems biology tools are particularly
suited for the identification of multi-targeted agents and drug synergistic effects. The complex-
ity of ALS pathobiology prompted us to use computational biology and machine learning tools
strategies to handle all data available and getting in silico relevant and integral information.
Systems biology is making important contributions to biomedical research [11], and it may
play a pivotal role in the future of drug discovery [12–14]. Recent drug development strategies
against Charcot-Marie-Tooth disease type I (CMT1A) and breast cancer highlight the power
of network pharmacological approaches for identifying drug combinations with high clinical
efficacy and low side effect risks [13]. Systems biology approaches have also been successfully
applied to identify novel proteins involved on Alzheimer’s disease [15,16]. Herein, we have
analysed public available data through systems biology approach to identify novel combina-
tions of repositioned drugs with neuroprotective potential for ALS.
Multicomponent Therapy for ALS by Networked Systems
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Materials and Methods
Systems Biology analysis for multicomponent drug discovery
TPMS (Anaxomics Biotech, Barcelona, Catalonia, Spain) is a top-down systems biology
approach with potential applications in drug repositioning [12,17,18].
Characterization of ALS. Through manual curation of the literature, we defined a set of
restrictions characterising ALS, which were used to build the protein network and the mathe-
matical model around ALS. We identified the main pathophysiological processes described to
be involved in ALS: glutamate excitotoxicity, protein misfolding and aggregation, mitochon-
drial dysfunction, oxidative stress, defective RNA processing and glia activation. Subsequently,
each pathophysiological process was further characterized at protein level. A total of 72 pro-
teins were used to focus the analysis on ALS in the human biological network (Table 1). The
details about the Uniprot ID of each protein and the bibliographic reference linking them with
ALS can be found in S1 Table.
The human biological network incorporates all the available relationships between proteins
from a regularly updated in-house database drawn from public sources: KEGG [19], REAC-
TOME [20], INTACT [21] BIOGRID [22], HDPR [23], MATRIXDB [24], MIPS [25], DIP
[26], MINT [27]. At the same time, the network was embedded with all sorts of biological
information (drug targets, tissue expression, biomarkers) about nodes (i.e. proteins) and edges
(i.e. connections) from public sources. The analysis of the network was focused in the area
around the proteins identified as important in ALS pathophysiology, including 2,455 proteins
and 65,044 relationships (30.228 from KEGG_XML, 6.651 from HPRD, 1.030 fromMatrixDB,
21.572 from Reactome, 8.908 from BIOGRID and 11.711 from INTACT). Average links per
node were 30,6.
The complexity of the network generated can be perceived in Fig 1A where a snapshots of
the full network visualized through the cytoscape software platform [28] is shown. For visualiz-
ing, modeling and analyzing molecular interaction of ALS network, the.cys version of the full
network is provided as Supp. Material. VCP, TARDBP, RGNEF are not included in the cytos-
cape ALS interactome since they are highly connected proteins (more than 200 known rela-
tionships), and FUS since there are not available information in public databases.
Repositioning analysis. Two complementary strategies are used to generate mathematical
models of living systems: an Artificial Neural Network (ANN) and Sampling Methods. ANNs
are supervised algorithms which identify relations between drug targets and clinical elements
of the network that are used for training a classifier with the information contained in
Table 1. Human biological network focused on ALS.
ALS pathophysiological
motives
N° of
seeds
Gene name
Glutamate excitotoxicity 11 SLC1A2, GRIA1, GRIA2, GRIA3, GRIA4, SOD1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D
Protein misfolding and
aggregation
23 SOD1, RNF19A, DERL1, MAP3K5, TARDBP, VCP, CSE1L, GRN, KPNA2, FUS, TNPO1, OPTN, NEFH,
PRPH, FIG4, BICD2, ALS2, MTOR, SQSTM1, VAPB, CHMP2B, HSPA1A, HSPA1B
Mitochondrial dysfunction 17 SOD1, KIF5B, MAPK11, MAPK11, MAPK12, MAPK13, MAPK14, DCTN1, KIFAP3, BCL2, Bcl-xL, XIAP,
BAD, BAX, cytochrome c, caspase-3, caspase-9, ANG
Oxidative Stress 6 SOD1, RAC1, NOX1, ERO1L, P4HB, PDIA3
Defective RNA processing 9 ANG, ELP3, FUS, FUS, SETX, SMN1, TARDBP, RGNEF, ATXN2, C9orf72
Glial activation 15 SLC1A2, SOD1, VEGFA, VEGFA, VEGFB, TNF, IL1B, CHGA, CHGB, SCG2, CD14, TLR2, IL4, IGF1,
CX3CR1, CX3CL1
Total number of seeds 81
Unique seeds 72
doi:10.1371/journal.pone.0147626.t001
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 3 / 17
DrugBank about drugs and indications [29,30], with capacity for predicting and scoring novel
potential drugs. The accuracy of the ANNs to reproduce the indications of Drugbank is 98%
for those drugs with all targets in the human biological network after applying a cross-fold vali-
dation process.
A total of 5440 drugs that generated approximately 14,794,080 of binary combinations were
screened, and some pre-analysis filters were applied (S5 Table). Combinations composed by
drugs with an outstanding safety profile with at least one known human target, with known
interactions and the known therapeutic target are inside the human biological network were
analysed. Within these 5440 drugs, there are subsets of drugs that share the target profile; these
drugs are considered as DrugBank synonyms. The drugs that share the target profile with
another one are not considered in the analysis, but are provided for the final drug candidate
Fig 1. Predicted MoA of CD1 and CD2multicomponent drugs. a. Snapshot of ALS network: snapshot of the full network visualized through the cytoscape
software platform. Nodes (traingles) represent proteins and links are functional interactions between proteins. The effector proteins of the different
pathophysiological motives (or effectors shared by several motives) are grouped and labelled in different colors. b and c. The graphs show the level of
activation or inhibition of each node depicted in the MoA representation of CD1 (b) and CD2 (c). The bars in grey correspond to proteins that are calculated to
be activated after the stimulation, and the bars in black correspond to proteins calculated to have reduced activity after the treatment with the stimulus. The
activity status of the proteins is the average of all the individuals included in the analysed population, and it is represented between 1 and -1, 1 meaning
activation and -1 inhibition of the gene/protein activity respect to the rest of the proteins involved in the MoA.
doi:10.1371/journal.pone.0147626.g001
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selection. A total of 134.940 binary combinations composed by non-synonymous drugs were
screened.
Combinations composed by approved drugs were sorted and selected by its relationship
with ALS or its corresponding motive, high synergism and their ability to cross the blood brain
barrier. Drugs with poor safety profile were further filtered out and those combinations previ-
ously related to ALS were also excluded. A total of 12 combinations Pimecrolimus + Pranlukast;
Alitretinoin + Pranlukast; Alitretinoin + Acamprosate; Thiethylperazine + Alitretinoin; Raloxi-
fene + Chloroquine; Pimecrolimus + Chloroquine; Pimecrolimus + Rasagiline; Acamprosate
+ Cinnarizine; Lisuride + Acamprosate; Acamprosate + Carphenazine; Methylergonovine
+ Acamprosate; Mefloquine + Alitretinoin. Lastly, we selected two combinations of reposi-
tioned drugs: Alitretinoin plus Pranlukast (CD1) and Alitretinoin plus Mefloquine (CD2) that
fulfilled all the criteria and had a novel, potentially beneficial MoA against ALS.
Sampling methods were used to describe with high capability all plausible relationship
between sets of proteins previously identified with ANNs. Sampling Methods generate mathe-
matical models that comply with a given set of restrictions, corresponding to the available bio-
logical knowledge about the constructed networks, together with knowledge derived from
DrugBank and GEO [31]. As the number of restrictions is always smaller than the number of
parameters required by the algorithm, any process modelled by TPMS has a “population” of
different solutions, which is set around 106–109, since this interval is estimated to faithfully
portray nature. Consequently, models result in both “global” predicted MoA, which account
for the majority of the population, and “cluster” mechanisms of action, which are more accu-
rate for population subgroups. A normalized synergism score (SE) is provided for the protein
involved in the synergism between the two drugs of the combination. SE accounts for the pon-
deration of the number of solutions that present the node of interest being affected by both
drugs, either in an additive, synergistic or antagonistic way, and the synergistic effect over the
node of both drugs (rather than additive). The maximum score according to this calculation is
0.5.
The MoA is validated in a two-step process. First, we checked that each link was accurate,
i.e., was already described in the literature. Second, we checked that the MoA made sense over-
all, featuring pathways coherent with the living system, the combinations of repositioned drugs
used for treatment and the known pathophysiology of ALS.
Spinal cord organotypic cultures
We used organotypic-based spinal cord cultures prepared from lumbar spinal cords of 8-day-
old Sprague-Dawley rat pups as previously described [32–34]. Briefly, lumbar spinal cords
were collected from pups and placed in ice-cold high glucose-containing (6.4 mg/ml) Gey’s
Balanced Salt Solution (GBSS) (Sigma-Aldrich, Steinheim, Germany). After removing menin-
ges and roots we cut the spinal cords into 350 μm transverse sections with a McIlwain Tissue
Chopper. We transferred four sections onto 30-mm-diameter Millipore Millicell-CM culture
(0.4 μm, Millipore, Billerica, USA) placed into 6-well plates (Thermo Fisher Scientific, Wal-
tham, MA, USA) containing 1 ml of culture medium, consisting in 50% (v/v) minimal essential
medium (MEM), 25 mMHepes, 25% (v/v) heat-inactivated horse serum, 2 mM glutamine and
25% (v/v) Hank’s Balanced Salt Solution (HBSS, Sigma) supplemented with 25.6 mg/ml glu-
cose; pH 7.2. Cultures were maintained at 37°C in a 5% CO2/95% air humidified environment.
We left cultures to stabilize for 1 week, and then changed the medium twice per week. Excito-
toxic insult consisted in the addition of 100 μM threohydroxyaspartate (THA) (for 1 to 4
weeks) [33]. We added concomitantly single drugs or in combination to assess the neuropro-
tective effect vs their vehicle controls (S2 Table); addition of riluzole (5 μM) was also assayed
Multicomponent Therapy for ALS by Networked Systems
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as positive control. Five cultures were performed in all experiments. The procedures involving
animals were approved by the Ethics Committee of Universitat Autònoma de Barcelona and
followed the European Communities Council Directive 2010/63/EU.
Immunohistochemistry
We fixed slices maintained in the different experimental conditions with 4% paraformaldehyde
in phosphate-buffered saline for 1h at RT. After blocking with 5% normal donkey serum (Vec-
tor Laboratories, Burlingame, CA, USA) and 0.2% Triton-X-100 in PBS (PBS-TX), we incu-
bated the sections with primary antibodies against anti-neurofilament heavy chain (NF-H or
SMI-32, 1:8000) and rabbit anti-ionized calcium binding adapter molecule 1 (Iba-1, 1:200)
(Wako, Tokyo, Osaka, Japan). For immunofluorescence, we thoroughly washed the cultures in
PBS with 0.2% Tween-20 (PBS-T) and incubated them with appropriate secondary antibody
Alexa Fluor1488 donkey anti-rabbit IgG (1:500) and Alexa Fluor1594 donkey anti-mouse IgG
(1:500) (Invitrogen Corp.; Carlsbad, CA, USA), diluted in PBS-T for 1 h at RT. Finally, cell
nuclei were labelled with DAPI (1:2000) for 1 min in PBS and the sections mounted with Fluor-
oamount-G medium (SouthernBiotech, Birmingham, AL, USA). We analysed the slides under
confocal microscope (Confocal Laser Scanning Microscope Zeiss LSM 700; Zeiss, Jena,
Germany).
Motoneuron counting and image analysis
We identified MNs in the slices by immunostaining with SMI-32 antibody and on the basis of
their morphology and size (Ø 25 μm) and their localization in the ventral horn of lumbar sec-
tions. All thoracic and sacral sections were out of counting. We blindly counted MNs meeting
these criteria in each spinal cord section. To count SMI-32 positive cells in the ventral horn of
organotypic spinal cord slices we used Z-stack confocal series. To quantify Iba-1 immunoreac-
tivity we selected the ventral horn of each spinal cord section. The microphotographs were
transformed to a grey scale and analyzed using ImageJ software. Immunoreactivity was
assessed by calculating the integrated density, after defining a threshold for background
correction.
Statistical analysis
Data are shown as mean ± SEM. An average of n = 5-days experiment were performed with
n = 4–5 biological replicates each day. Statistical significance (p<0.05) between culture treat-
ments was determined by one-way ANOVA followed by Dunnett’s post-hoc test.
Results
Identification of putative neuroprotective polypharmacology for ALS
The repositioning analysis based on systems biology approach applying ANN identified two
drug combinations from the repository: Alitretinoin plus Pranlukast (CD1) and Alitretinoin
plus Mefloquine (CD2). They may be potentially useful to treat ALS, with a focus on tackling
the disease from several angles at a time.
Aliretinoin is an active agent to treat psoriasis with an agonistic effect on retinoic receptors
that could activate spinal cord repair mechanisms and modulate the inflammatory reaction
[35–37]. Because of its potential benefits on neuroprotection, alitretinoin was included in both
combinations CD1 and CD2. In CD1 included also Pranlukast, an agent used against ashma
and allergy that exerts anti-inflammatory effects because it inhibits CysLT1 receptor, nuclear
factor kappa B (NFƙB) and TNFα, suggesting a possible suppressive effect on the spinal cord
Multicomponent Therapy for ALS by Networked Systems
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inflammation and neutrophil infiltration [38]. CD2 includes Alitretinoin combined with Mef-
loquine, employed to treat malaria, which may prevent glia activation and glutamate
excitotoxicity.
Drug combinations exert motor neuron protection
In order to perform a preclinical screening of the selected drug combinations we used an spinal
cord organotypic-based culture (SCOCs) because it retains many organizational features of the
spinal cord, such as neuronal circuitry, relatively well-preserved cellular architecture and glial–
neuronal interactions [5,32,34]. A well-established in vitro model for ALS is obtained by pro-
ducing progressive chronic glutamate excitotoxicity by the addition of THA, an inhibitor of
glutamate transport, in the culture [33,39–42]. After 7DIV, we administered THA accompa-
nied by either vehicle or each drug combination at estimated optimal concentrations. We esti-
mated these concentrations by inferring the information available from clinical uses and
pharmacokinetic studies in rat. After 4 weeks post-excitotoxic insult controls and vehicle-
treated SCOCs showed similar numbers of surviving MNs (Fig 2A). As expected, we observed
a significant reduction in the number of MNs in the slices treated with THA alone (10±2) com-
pared with control slices (27±2). In contrast, slices treated with THA plus CD1, CD2 or riluzole
(5 μM), used as a positive control, presented a significant neuroprotective effect on MNs pres-
ervation (20±2, 19±3 and 29±4, respectively) (Fig 2A–2B).
To test the synergism of the combined compounds, we analysed the effects on MNs survival
on treated-SCOCs with each separate drug of CD1 and CD2 combinations: Mefloquine, Alire-
tinoin and Pranlukast. We found that, while combinations preserve MNs, each compound
alone had no neuroprotective effect on the excitotoxic-injured SCOCs (Fig 3). MNs treated
with single drugs showed disrupted neurites compared with controls and they presented a
degenerating appearance like control THA-treated slices.
Molecular mechanism prediction
Sampling methods were applied to identify the mechanisms of action of the three drugs
selected from the reprofiling results. 181 proteins have been identified in the MoA of CD1, cor-
responding to the synergic action of pranlukast and alitretinoin (S3 Table). 94 proteins have
been identified in the MoA of CD2, corresponding to the synergic action of mefloquine and ali-
tretinoin (S4 Table). We observed that both drug combinations downregulated all forms of
p38MAPKs proteins, called as MK 11–14, which have been already reported to have a role in
ALS pathology and in inflammation (Fig 1B and 1C) [43–45].
Drug combinations reduce microglial reactivity
Since glial cells are important contributors to inflammatory state and ALS pathology we ana-
lysed microglial reactivity and morphology in SCOCs by immunohistochemistry (Fig 4). Slices
treated with the different vehicles presented the same pattern of Iba-1 labeling, and microglial
morphology that control cultures (not shown), corresponding to resting microglial cells with
small cell bodies and thin processes. Reactive microglia increase in size and thicken and
shorten their processes in early stages to become amoeboid microglia with phagocytic activity
[46,47]. We observed that microglia became reactive with amoeboid morphology due to THA
treatment of the slices (Fig 4). The slices treated with THA plus CD1 or CD2 presented a phe-
notype ramified-resting and similar to control SCOCs (Fig 4B, middle panel). Addition of the
single compounds, Mefloquine, Aliretinoin and Pranlukast to the injured cultures did not pre-
vent the amoeboid reactive microglia phenotype induced by THA treatment (Fig 5). These
Multicomponent Therapy for ALS by Networked Systems
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results suggest that CD1 and CD2 are promising for reducing microgliosis in ALS, but not the
individual components.
Discussion
Systems biology was used as strategy to identify new combinatorial drugs with enough evi-
dences to be promising for the treatment of human patients with ALS. In addition, we
described their MoA and point to new human signalling targets for ALS. The up-to-date tech-
nology and filters used may allow for quickly move towards phase II/III trials in their way to
clinical translation of the drug combinations composed by Alitretinoin plus Pranlukast (CD1)
or Alitretinoin plus Mefloquine (CD2). However, further experiments in vivo should be done
in to perform a safe translation to human.
Failure of multiple treatment options proposed for ALS to have a positive outcome in clini-
cal trials has led to a frustrating reduction of trials. Many treatment assays have been based on
the knowledge of etiopathogenic events mostly found by using transgenic mice carrying super-
oxide dismutase 1 (SOD1) ALS linked mutations. Moreover, lack of reliable early biomarkers
makes it difficult early treatment, which it is often initiated in late phases of the disease. Our
study is based on data gathered from human pathology and models in their late stages, thus
searching for potential treatments that may be useful in the clinical setting.
Fig 2. In silico design of polypharmacology for neuroprotection in an in vitromodel of ALS. a. Left,
Schematic drawing indicating the site of analysis (white frame) of MN survival at the ventral horn of the spinal
cord slice.Middle and right, Representative microphotographs of MNs in the ventral horn of the spinal cord
slice detected by immunohistochemistry with the SMI-32 antibody at 4 weeks after THA treatment.Mid
panels show control culture and with addition of vehicle (v) for each drug combination (CD1-CD2) or riluzole.
Right panels show cultures subjected to excitotoxicity by THA alone or with co-treatment with CD1 and CD2
drug combinations or riluzole. Scale bar, 50 μm. b. Bar graph showing the number (mean±SEM, n = 5) of
SMI-32 positive cells in the ventral horn of each spinal cord slice. (***p<0.001; *p<0.05 by Dunnett’s post-
hoc test vs THA condition).
doi:10.1371/journal.pone.0147626.g002
Fig 3. Lack of neuroprotection exerted by single drugs. a. Representative microphotograhs of SMI-32 at 4 weeks after excitotoxic treatment stained MNs
after co-treatment with THA plus CD1 and CD2 components: Aliretinoin (Ali), Mefloquine (Meflo) and Pranlukast (Pran). b. Bar graph showing the number of
SMI-32 positive neurons in the ventral horn of each spinal cord slice obtained after each treatment. (mean±SEM, n = 5). No significant differences comparing
each drug treatment by Dunnett’s post-hoc test vs THA condition.
doi:10.1371/journal.pone.0147626.g003
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Our blind screen of existing compounds against the multitude of ALS-specific targets identi-
fied possible combinations of off-patent drugs in cell-based assays. Previous similar studies had
found that two drugs with different indications (an antipsychotic and an antiprotozoal) exhibit
an unexpected anti-tumoral activity [48]. We found that two predicted combinations target
two of the main processes related to ALS: excitotoxicity and neuroinflammation. Related to the
former, as mentioned, riluzole, the only compound that presents limited benefits in ALS
patients, exerts it effect mainly by reducing excitotoxicity. Other compounds such as
Fig 4. Reduction of microgliosis by drug combinations CD1 and CD2. a. Schematic drawing indicating the site of analysis (white frame) of microgliosis at
the ventral horn of the spinal cord slice. b. Top panels are representative microphotographs showing microglia stained with anti-Iba1 (green) at 3 weeks post-
THA treatment alone or co-treated with each drug combination or riluzole.Middle panels are profile drawings of microglia showing the ameboid-like or
ramified shape acquired after each treatment. Bottom panels, representative microphotographs of the merge fluorescent staining with anti-Iba1, DAPI and
MNs stained with SMI-32. Scale bar, 20 μm. c. Bar graph showing the microglial reactivity of each experimental condition by measuring the
immunofluorescence intensity of Iba-1 in the ventral horn of each spinal cord slice. (mean±SEM, n = 5) (***p<0.001; by Dunnett’s post-hoc test vs THA
condition).
doi:10.1371/journal.pone.0147626.g004
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ceftriaxone that specifically increases the expression of glial glutamate transporters in astro-
cytes, prolongs survival in the tgSODG93A [49]. However, although phase I and II clinical trials
were successful, a phase III clinical trial investigating the effect of ceftriaxone was negative [50].
On the other hand, microglia actively contributes to the disease pathogenesis, since specific
deletion of mutant SOD1 in microglia significantly prolongs survival in the tgSODG93A model
[51]. Microglia acquires an activated state during the disease process [52], characterized by cell
body enlargement and thick processes, and get properties of antigen-presenting cells and start
to interact with T-cells, which infiltrate the affected spinal cord and cortex [53,54]. This micro-
glial activation starts shortly before clinical onset of the disease, and the number of activated
glia and infiltrated T-cells increases with disease progression [53,55]. Different strategies tar-
geting inflammation have already been investigated. General immunosuppression or immuno-
modulation has been ineffective [56]. Celecoxib, a cyclooxygenase 2 (COX2) inhibitor, was
effective in the tgSODG93A, but not in patients [50]. Attempts to neutralize the released ROS
with vitamin E, creatine or coenzyme Q10 (CoQ10) were unsuccessful in patients [4].
TPMS technology is capable to reveal drugable signalling targets and screen drug libraries to
end up with effective combinations for complex pathological situation. We found that the com-
bined use of Alitretinoin and Pranlukast (CD1) produced MN preservation and reduced
microgliosis in the ALS in vitro model. Pranlukast is a selective antagonists of the cysLTR1 and
can modulate inflammation though cyclic nucleotide phosphodiesterases, 5’-lypoxigenase and
by suppressing the proinflammatory transcription factor NFƙB [57,58]. Alitretinoin or 9-cis-
Fig 5. Lack of anti-inflammatory effect exerted by single drugs. a.Representative microphotograhs of
microglia and DAPI at 3 weeks after co-treatment with THA alone or plus single components of the
neuroprotective combinations (CD1 and CD2): Aliretinoin (Ali), Mefloquine (Meflo) and Pranlukast (Pran)
(n = 5). Right panels are profile drawings of microglia showing the ameboid-like or ramified shape acquired
after each treatment. b. Bar graph showing the microglial reactivity of each experimental condition by
measuring the immunofluorescence intensity of Iba-1 in the ventral horn of each spinal cord slice. (mean
±SEM, n = 5) (*p<0.05; by Dunnett’s post-hoc test vs THA condition).
doi:10.1371/journal.pone.0147626.g005
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retinoic acid is a panagonist retinoid, capable of binding to all six known retinoid receptors.
Aliretinoin is used to improve skin-related diseases such as dermatitis or Kaposi’s sarcoma
[35]. However, neither of these drugs exert neuroprotection when administered alone. Curi-
ously, the benefits obtained by Alitretinoin were also obtained with the simultaneous addition
of Mefloquine, a 4-quinolinemethanol antimalarial and antiparasitic drug structurally related
to quinine.
Both drug combinations tested prevented MN death induced by chronic excitotoxicity.
Such effect may be associated to anti-excitotoxic effect by inhibiting p38MAPK. Rho-mediated
calcium-dependent activation of p38αMAPK has been described as a trigger of excitotoxic cell
death [43]. The MoA analyses indicate that both drug combinations exert an inhibitory effect
over the four p38MAPK proteins: β, γ, α and δ (on results named as MK11, MK12, MK13 and
MK14). It is known that persistent activation of p38MAPK in the SOD1G93A mice correlates
with disease progression [44], and that its inhibition in an in vitro excitotoxicity ALS model
rescues MNs from cell death [45].
Regarding the inflammatory response, both combinations may regulate pro-inflammatory
cytokines, such as interleukine-1β (IL1-β) and TNF-α. At late stages of ALS, microglia become
non-responsive and dystrophic, a phenotype that follows the chronic activation and the release
of these pro-inflammatory cytokines. Activation of TNFR1 in neurons classically leads to apo-
ptosis but also increases AMPA receptors in the membrane [10]. We observed that combina-
tions CD1 and CD2 promoted a shift to a resting microglia phenotype concomitant with a
slight reduction of TNFα production which will be likely beneficial in helping MN survival.
Microglia present an extremely cellular plasticity switching from a “resting” phenotype with
fine processes to a globular “amoeboid” activated phenotype with the ability to migrate to sites
of damage, phagocyte cellular debris and have toxic effects on neurons.
The dual treatment with Aliretinoin and Mefloquine (CD2) may induce the activation of
the heterodimer composed by peroxisome proliferator-activated receptors (PPARG), retinoid
X receptor (RXR) and transmembrane phosphoprotein (CBP). PPARs are ligand-activated
transcription factors that play pivotal roles in the regulation of a large number of biological
processes including inflammation. PPARs readily heterodimerize with the RXR prior to ligand
binding [59]. After ligand binding, the PPAR/RXR heterodimer stably binds on genomic DNA
at specific sites called peroxisome proliferator response element (PPRE) and upregulates gene
transcription. Pioglitazone, an agonist of PPARG have recently suggested to improve locomo-
tor function in a TDP-43 fly model [60].
Interestingly, dual treatment of Aliretinoin and Pranlukast may exert some additional pro-
tein regulation beyond those related with inflammation and excitotoxicity. This CD1 could
play a role on regulation of ataxin-2 (ATX2). There is increasing evidence that alterations in
RNA processing, predominantly mediated by the two RNA-binding proteins TDP-43 and
FUS, may be relevant to ALS-frontotemporal dementia complex (FTLD) [61]. A potent modi-
fier of the FUS pathology is an intermediate repeat length in the ATX2 gene. The survival
motor neuron (SMN) protein may be also upregulated by CD1 by an unknown mechanism to
be explored. SMN protein is significantly reduced in the spinal cord of patients with sporadic
ALS, and neuronal overexpression of SMN significantly preserved locomotor function, rescued
MNs, and attenuated astrogliosis in spinal cords of SOD1G93A mice [62]. Another protein,
VAPB, whose mutations have been linked to a loss of function in ALS, might be activated by
CD1. ALS-linked mutated VAPB behaves in a dominant negative manner, sequestering wild
type protein into cytoplasmic inclusions, and it was recently published a genetic network that
includes other ALS genes such as sod1, tdp43, in addition to tor which is also a key regulator in
autophagy and cell metabolism [63].
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Recent successful results in the network biology field, such as the one addressed here, have
attracted interest towards how systemic approaches might increase the revenue of the drug dis-
covery process [14]. We found that in silico predicted combinations formed by Alitretinoin
and Pranlukast (CD1) or Alitretinoin and Mefloquine (CD2) exerted effective neuroprotection
in an in vitromodel of ALS by reducing the toxic effects of chronic excitotoxicity on both
microglia reactivity and MN survival. This drug repurposing seems of interest for further pre-
clinical investigations with a perspective on clinical trials in patients.
Conclusions
Here we demonstrated that systems biology approach is useful to find new drugs for the treat-
ment of ALS. The polypharmacology proposed herein represented the first system-based tar-
geting approach for ALS, which has not been addressed before. We demonstrated that in silico
predictions are powerful enough to discover new and efficient therapies like the combinations
proposed: Aliretinoin and Pranlukast or Aliretinoin and Mefloquine, which reduce microglio-
sis and rescue MNs under excitotoxic damage.
Supporting Information
S1 Table. Molecular characterization of the Pathophysiological motives causing ALS and
effector proteins associated to each motive according to the literature search.
(DOCX)
S2 Table. Drug combinations for the treatment of ALS identified by TPMS.
(DOCX)
S3 Table. Synergy targets of the Alitretinoin Pranlukast (CD1).
(DOCX)
S4 Table. Synergy targets of the Alitretinoin and Mefloquine (CD2).
(DOCX)
S5 Table. Summary of binary drugs combination screening.
(DOCX)
Acknowledgments
We want to thank to Marta Morell and Jessica Jaramillo for their technical support.
Author Contributions
Conceived and designed the experiments: CC MCMHG PA. Performed the experiments:
MHG RM. Analyzed the data: MHG RMMC. Contributed reagents/materials/analysis tools:
MHG CC RMMC. Wrote the paper: MHG CCMC. Helped to design in vitro experiments:
XN. Helped to design computational study: AP JMM.
References
1. Rowland L, Shneider N. Amyotrophic lateral sclerosis. N Engl J Med [Internet]. 2001; 344:1688–700.
Available from: http://www.nejm.org/doi/full/10.1056/NEJM200105313442207 PMID: 11386269
2. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in
amyotrophic lateral sclerosis. N Engl J Med. 1994; 330:585–91. PMID: 8302340
3. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neu-
ron disease (MND). Cochrane Database of Systematic Reviews. 2007.
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 13 / 17
4. Poppe L, Rué L, Robberecht W, Van Den Bosch L. Translating biological findings into new treatment
strategies for amyotrophic lateral sclerosis (ALS). Exp Neurol. Elsevier B.V.; 2014 Jul;
5. Guzman-Lenis MS, Navarro X, Casas C. Drug screening of neuroprotective agents on an organotypic-
based model of spinal cord excitotoxic damage. Restor Neurol Neurosci. 2009; 27(4):335–49. doi: 10.
3233/RNN-2009-0482 PMID: 19738326
6. Wu Y, Satkunendrarajah K, Fehlings MG. Riluzole improves outcome following ischemia-reperfusion
injury to the spinal cord by preventing delayed paraplegia. Neuroscience. 2014 Apr; 265:302–12. doi:
10.1016/j.neuroscience.2014.01.059 PMID: 24508749
7. Lattante S, Rouleau G a, Kabashi E. TARDBP and FUSmutations associated with amyotrophic lateral
sclerosis: summary and update. HumMutat. 2013; 34:812–26. doi: 10.1002/humu.22319 PMID:
23559573
8. Cozzolino M, Ferri A, Valle C, Teresa M. Molecular and Cellular Neuroscience Mitochondria and ALS:
Implications from novel genes and pathways. Mol Cell Neurosci. Elsevier Inc.; 2013; 55:44–9. PMID:
22705710
9. Ferraiuolo L, Kirby J, Grierson a J, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in
amyotrophic lateral sclerosis. Nat Rev Neurol [Internet]. 2011; 7:616–30. Available from: http://www.
nature.com/nrneurol/journal/v7/n11/pdf/nrneurol.2011.152.pdf\npapers://2869f907-86c9-45b4-b3a1-
9fd72ada1eca/Paper/p53665 doi: 10.1038/nrneurol.2011.152 PMID: 22051914
10. Casas C, Manzano R, Vaz R, Osta R, Brites D. Synaptic Failure: Focus in an Integrative View of ALS.
Brain Plast. 2014;23 Decembe:1–16.
11. Casas C, Isus L, Herrando-Grabulosa M, Mancuso FM, Borrás E, Sabidó E, et al. Network-based prote-
omic approaches reveal the neurodegenerative, neuroprotective and pain-related mechanisms
involved after retrograde axonal damage. Sci Rep [Internet]. 2015; 5:9185. Available from: http://www.
nature.com/doifinder/10.1038/srep09185 doi: 10.1038/srep09185 PMID: 25784190
12. Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery.
Trends Pharmacol Sci. 2010; 31(February):115–23.
13. Jaeger S, Aloy P. From protein interaction networks to novel therapeutic strategies. IUBMB Life. 2012.
p. 529–37. doi: 10.1002/iub.1040 PMID: 22573601
14. Zanzoni A, Aloy P. A network medicine approach to human disease. FEBS Lett. Federation of Euro-
pean Biochemical Societies; 2009; 583(11):1759–65.
15. Soler-López M, Zanzoni A, Lluís R, Stelzl U, Aloy P. Interactome mapping suggests new mechanistic
details underlying Alzheimer’s disease. Genome Res. 2011; 21:364–76. doi: 10.1101/gr.114280.110
PMID: 21163940
16. Soler-Lopez M, Badiola N, Zanzoni A, Aloy P. Towards Alzheimer’s root cause: ECSIT as an integrating
hub between oxidative stress, inflammation and mitochondrial dysfunction. BIOESSAYS. 2012;
34:532–41. PMID: 22513506
17. Valls R, Pujol A, Artigas L. Anaxomics’methodologies: understanding the complexity of biological pro-
cesses. white Pap. 2013;
18. Perera S, Artigas L, Mulet R, Mas JM, Sardón T. Systems biology applied to non-alcoholic fatty liver dis-
ease (NAFLD): treatment selection based on the mechanism of action of nutraceuticals. Nutrafoods.
2014; 13(2):61–8.
19. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et al. From genomics to
chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006; 34(Database issue):
D354–7. PMID: 16381885
20. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase.
Nucleic Acids Res [Internet]. 2014; 42(Database issue):D472–7. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3965010&tool=pmcentrez&rendertype=abstract doi:
10.1093/nar/gkt1102 PMID: 24243840
21. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C, et al. The IntAct molecular inter-
action database in 2012. Nucleic Acids Res. 2012; 40(D1).
22. Salwinski L, Licata L, Winter A, Thorneycroft D, Khadake J, Ceol A, et al. Recurated protein interaction
datasets. Nature methods. 2009. p. 860–1. doi: 10.1038/nmeth1209-860 PMID: 19935838
23. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human
Protein Reference Database—2009 update. Nucleic Acids Res [Internet]. 2009; 37(Database):D767–
72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2686490&tool=
pmcentrez&rendertype=abstract doi: 10.1093/nar/gkn892 PMID: 18988627
24. Chautard E, Fatoux-Ardore M, Ballut L, Thierry-Mieg N, Ricard-Blum S. MatrixDB, the extracellular
matrix interaction database. Nucleic Acids Res [Internet]. 2011; 39(Database issue):D235–40.
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 14 / 17
Available from: http://nar.oxfordjournals.org/content/early/2010/09/17/nar.gkq830.short doi: 10.1093/
nar/gkq830 PMID: 20852260
25. Mewes HW, Ruepp A, Theis F, Rattei T, Walter M, Frishman D, et al. MIPS: Curated databases and
comprehensive secondary data resources in 2010. Nucleic Acids Res. 2011; 39(November 2010):220–
4.
26. Xenarios I, Fernandez E, Salwinski L, Duan XJ, Thompson MJ, Marcotte EM, et al. DIP: The Database
of Interacting Proteins: 2001 update. Nucleic Acids Res. 2001; 29(1):239–41. PMID: 11125102
27. Chatr-Aryamontri A, Zanzoni A, Ceol A, Cesareni G. Searching the protein interaction space through
the MINT database. Funct Proteomics Methods Mol Biol Clift NJ [Internet]. 2008; 484(January
2007):305–17. Available from: http://www.springerlink.com/index/10.1007/978-1-59745-398-1
28. Lopes CT, Franz M, Kazi F, Donaldson SL, Morris Q, Bader GD. CytoscapeWeb: an interactive web-
based network browser. Bioinformatics [Internet]. 2010; 26(18):2347–8. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=2935447&tool=pmcentrez&rendertype=abstract doi:
10.1093/bioinformatics/btq430 PMID: 20656902
29. Wishart TM, Rooney TM, Lamont DJ, Wright AK, Morton a J, Jackson M, et al. Combining comparative
proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degenera-
tion in vivo. PLoS Genet [Internet]. 2012 Jan [cited 2013 Apr 9]; 8(8):e1002936. Available from: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3431337&tool=pmcentrez&rendertype=abstract
doi: 10.1371/journal.pgen.1002936 PMID: 22952455
30. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehen-
sive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006; 34:D668–72. PMID:
16381955
31. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for
functional genomics data sets—Update. Nucleic Acids Res. 2013; 41(November 2012):991–5.
32. Guzman-Lenis MS, Vallejo C, Navarro X, Casas C. Analysis of FK506-mediated protection in an orga-
notypic model of spinal cord damage: heat shock protein 70 levels are modulated in microglial cells.
Neuroscience. 2008; 155(1):104–13. doi: 10.1016/j.neuroscience.2008.04.078 PMID: 18577426
33. Rothstein J, Jin L, Dykes-Hoberg M, Kuncl R. Chronic inhibition of glutamate uptake produces a model
of slow neurotoxicity. Proc Natl Acad Sci U S A. 1993; 90:6591–5. PMID: 8393571
34. Herrando-Grabulosa M, Casas C, Aguilera J. The C-terminal domain of tetanus toxin protects motoneu-
rons against acute excitotoxic damage on spinal cord organotypic cultures. J Neurochem. 2013;
124:36–44. doi: 10.1111/jnc.12062 PMID: 23106494
35. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. 2008;437–44.
36. Malaspina A, Turkheimer F. A review of the functional role and of the expression profile of retinoid sig-
naling and of nuclear receptors in human spinal cord. Brain Res Bull. 2007; 71:437–46. PMID:
17259011
37. Jokic N, Ling YY, Ward RE, Michael-Titus AT, Priestley J V., Malaspina A. Retinoid receptors in chronic
degeneration of the spinal cord: Observations in a rat model of amyotrophic lateral sclerosis. J Neuro-
chem. 2007; 103:1821–33. PMID: 17956549
38. Tomari S, Matsuse H, Machida I, Kondo Y, Kawano T, Obase Y, et al. Pranlukast, a cysteinyl leukotri-
ene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and
nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics.
Clin Exp Allergy. 2003; 33:795–801. PMID: 12801315
39. Corse a M, Bilak MM, Bilak SR, Lehar M, Rothstein JD, Kuncl RW. Preclinical testing of neuroprotective
neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis [Internet]. 1999
Oct; 6(5):335–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10527802 PMID: 10527802
40. Lee S, Kim Y, Li E, Park S. Ghrelin Protects Spinal Cord Motoneurons Against Chronic Gluta- mate
Excitotoxicity by Inhibiting Microglial Activation. 2012; 16:43–8.
41. Lim E, Lee S, Li E, Kim Y, Park S. Ghrelin protects spinal cord motoneurons against chronic glutamate-
induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3β
pathways. Exp Neurol [Internet]. Elsevier Inc.; 2011 Jul [cited 2014 Aug 11]; 230(1):114–22. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/21530509 doi: 10.1016/j.expneurol.2011.04.003 PMID:
21530509
42. Tolosa L, Caraballo-Miralles V, Olmos G, Lladó J. TNF-α potentiates glutamate-induced spinal cord
motoneuron death via NF-κB. Mol Cell Neurosci [Internet]. Elsevier Inc.; 2011 Jan [cited 2014 Aug 11];
46(1):176–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20849956 doi: 10.1016/j.mcn.
2010.09.001 PMID: 20849956
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 15 / 17
43. Semenova MM, Mäki-Hokkonen AMJ, Cao J, Komarovski V, Forsberg KM, Koistinaho M, et al. Rho
mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat Neu-
rosci. 2007; 10(4):436–43. PMID: 17369826
44. Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, Giorgini A, et al. Persistent activation of p38
mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates
with disease progression. Mol Cell Neurosci. 2003; 23:180–92. PMID: 12812752
45. Lladó J, Tolosa L, Olmos G. Cellular and molecular mechanisms involved in the neuroprotective effects
of VEGF on motoneurons. Front Cell Neurosci [Internet]. 2013; 7(October):181. Available from: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3803143&tool=pmcentrez&rendertype=abstract
46. Streit W, Kreutzberg G. Response of endogenous glial cells to motor neuron degeneration induced by
toxic ricin. J Comp Neurol. 1988; 268:248–63. PMID: 3360987
47. Stence N, Waite M, Dailey M. Dynamics of microglial activation: a confocal time-lapse analysis in hippo-
campal slices. Glia. 2001; 33:256–66. PMID: 11241743
48. Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, et al. The novel combination of chlor-
promazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Can-
cer Res. 2007; 67:11359–67. PMID: 18056463
49. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics
offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433(7021):73–7.
PMID: 15635412
50. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of cele-
coxib in amyotrophic lateral sclerosis. Ann Neurol. 2006; 60(1):22–31. PMID: 16802291
51. Boillée S, Vande Velde C, Cleveland DW. ALS: A Disease of Motor Neurons and Their Nonneuronal
Neighbors. Neuron. 2006; 52:39–59. PMID: 17015226
52. Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, et al. Evidence of widespread
cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission
tomography study. Neurobiol Dis. 2004; 15(3):601–9. PMID: 15056468
53. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates
with disease progression. Neurology. 2001; 57(7):1282–9. PMID: 11591849
54. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclero-
sis. Arch Neurol. 1993; 50(1):30–6. PMID: 8093428
55. Beers DR, Henkel JS, ZhaoW, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow dis-
ease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci
U S A. 2008; 105(40):15558–63. doi: 10.1073/pnas.0807419105 PMID: 18809917
56. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in
motor neuron disease. The Lancet Neurology. 2011. p. 253–63. doi: 10.1016/S1474-4422(11)70015-1
PMID: 21349440
57. Theron a J, Steel HC, Tintinger GR, Gravett CM, Anderson R, Feldman C. Cysteinyl leukotriene recep-
tor-1 antagonists as modulators of innate immune cell function. J Immunol Res [Internet]. Hindawi Pub-
lishing Corporation; 2014 Jan [cited 2014 Aug 11]; 2014:608930. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=4058211&tool=pmcentrez&rendertype=abstract doi:
10.1155/2014/608930 PMID: 24971371
58. Okubo M, Yamanaka H, Kobayashi K, Noguchi K. Leukotriene synthases and the receptors induced by
peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain. Glia [Internet].
2010 Apr [cited 2014 Aug 11]; 58(5):599–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
19908283 doi: 10.1002/glia.20948 PMID: 19908283
59. Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B. Fluorescence imaging reveals
the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in
the absence and presence of ligand. J Biol Chem. 2005; 280(18):17880–90. PMID: 15731109
60. Joardar A, Menzl J, Podolsky TC, Manzo E, Estes PS, Ashford S, et al. PPAR gamma activation is neu-
roprotective in a Drosophila model of ALS based on TDP-43. HumMol Genet [Internet]. 2015; 24
(6):1741–54. Available from: http://www.hmg.oxfordjournals.org/cgi/doi/10.1093/hmg/ddu587 doi: 10.
1093/hmg/ddu587 PMID: 25432537
61. Droppelmann CA, Campos-Melo D, Ishtiaq M, Volkening K, Strong MJ. RNAmetabolism in ALS: When
normal processes become pathological. Amyotroph Lateral Scler Frontotemporal Degener [Internet].
2014;(November 2013):1–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24555412
62. Turner BJ, Alfazema N, Sheean RK, Sleigh JN, Davies KE, Horne MK, et al. Overexpression of survival
motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1mice. Neu-
robiol Aging. 2014; 35:906–15. doi: 10.1016/j.neurobiolaging.2013.09.030 PMID: 24210254
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 16 / 17
63. Deivasigamani S, Verma HK, Ueda R, Ratnaparkhi A, Ratnaparkhi GS. A genetic screen identifies Tor
as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis. Biol Open [Internet].
2014; 3:1127–38. Available from: http://bio.biologists.org/cgi/doi/10.1242/bio.201410066 doi: 10.1242/
bio.201410066 PMID: 25361581
Multicomponent Therapy for ALS by Networked Systems
PLOSONE | DOI:10.1371/journal.pone.0147626 January 25, 2016 17 / 17
